BRIEF published on 02/18/2026 at 07:35, 15 days 6 hours ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
BRIEF published on 02/18/2026 at 07:35, 15 days 6 hours ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
PRESS RELEASE published on 02/18/2026 at 07:30, 15 days 6 hours ago Inside Information / Other news releases GenSight Biologics strengthens Regulatory Affairs & Quality team with two key appointments to support global regulatory strategy and upcoming milestones in gene therapy for retinal diseases Quality Regulatory Affairs GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 02/10/2026 at 07:35, 23 days 6 hours ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
BRIEF published on 02/10/2026 at 07:35, 23 days 6 hours ago GenSight Biologics Begins REVISE Study for GS010 Therapy GenSight Biologics LHON REVISE Study GS010 Therapy 15-20 National Hospital
PRESS RELEASE published on 02/10/2026 at 07:30, 23 days 6 hours ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 1 month 7 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 1 month 7 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 2 months 7 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
PRESS RELEASE published on 12/29/2025 at 08:00, 2 months 7 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
Published on 03/05/2026 at 13:40, 19 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 29 minutes ago Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend
Published on 03/05/2026 at 13:30, 29 minutes ago Nextech3D.ai Expands AI Event Technology Into New Markets and Implements 20%-30% Enterprise Price Increase
Published on 03/05/2026 at 13:00, 59 minutes ago Revolve Signs Definitive Agreements for Portfolio of 16 Distributed Generation Solar Projects in Mexico
Published on 03/05/2026 at 13:00, 59 minutes ago Field Work Identifies New Mineralized Trend and Additional Gold Targets at Golden Rose
Published on 03/05/2026 at 13:43, 16 minutes ago Healthcare specialist SHS Capital exits AMW, a leading specialty pharma company, and continues partnership by reinvesting with its current fund as part of a syndicate of investors
Published on 03/05/2026 at 13:25, 34 minutes ago Huawei and SOLUM Unveil Shop-in-Shop Smart Converged Network Solution to Accelerate Retail Intelligence
Published on 03/05/2026 at 13:06, 52 minutes ago HENSOLDT acquires Nedinsco and expands its European presence
Published on 03/05/2026 at 13:05, 54 minutes ago Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales
Published on 03/05/2026 at 13:00, 59 minutes ago Huawei Launches AI Data Platform to Bridge Models and Business Value
Published on 03/04/2026 at 23:50, 14 hours 9 minutes ago Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 19 hours 59 minutes ago Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 20 hours 14 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
